Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 124082, 18 pages
http://dx.doi.org/10.1155/2015/124082
Research Article

Proteomic Study to Survey the CIGB-552 Antitumor Effect

1Department of Proteomics, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba
2Department of Bioinformatics, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba
3Pharmaceutical Department, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba

Received 11 March 2015; Accepted 26 August 2015

Academic Editor: Zheng Li

Copyright © 2015 Arielis Rodríguez-Ulloa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

CIGB-552 is a cell-penetrating peptide that exerts in vitro and in vivo antitumor effect on cancer cells. In the present work, the mechanism involved in such anticancer activity was studied using chemical proteomics and expression-based proteomics in culture cancer cell lines. CIGB-552 interacts with at least 55 proteins, as determined by chemical proteomics. A temporal differential proteomics based on iTRAQ quantification method was performed to identify CIGB-552 modulated proteins. The proteomic profile includes 72 differentially expressed proteins in response to CIGB-552 treatment. Proteins related to cell proliferation and apoptosis were identified by both approaches. In line with previous findings, proteomic data revealed that CIGB-552 triggers the inhibition of NF-κB signaling pathway. Furthermore, proteins related to cell invasion were differentially modulated by CIGB-552 treatment suggesting new potentialities of CIGB-552 as anticancer agent. Overall, the current study contributes to a better understanding of the antitumor action mechanism of CIGB-552.